Annual report
2914.TEDINET S100QG4E
Period2022-01-01 → 2022-12-31
Filed2023-03-24
StandardIFRS
ConsolidatedYes
Data checks21 of 21 passed
Key figures · 157
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥2.66T | 2022-01-01 → 2022-12-31 | Cons. | Revenue IFRS |
| Revenue | ¥2.32T | 2021-01-01 → 2021-12-31 | Cons. | Revenue IFRS |
| Revenue | ¥2.09T | 2020-01-01 → 2020-12-31d | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥2.18T | 2019-01-01 → 2019-12-31d | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥2.22T | 2018-01-01 → 2018-12-31d | Cons. | Revenue IFRS (5-year summary) |
| Operating income | ¥653.6bn | 2022-01-01 → 2022-12-31 | Cons. | Operating profit loss IFRS |
| Operating income | ¥499.0bn | 2021-01-01 → 2021-12-31 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥593.5bn | 2022-01-01 → 2022-12-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥472.4bn | 2021-01-01 → 2021-12-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥420.1bn | 2020-01-01 → 2020-12-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥465.2bn | 2019-01-01 → 2019-12-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥531.5bn | 2018-01-01 → 2018-12-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Net income (owners) | ¥442.7bn | 2022-01-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥338.5bn | 2021-01-01 → 2021-12-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥310.3bn | 2020-01-01 → 2020-12-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥348.2bn | 2019-01-01 → 2019-12-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥385.7bn | 2018-01-01 → 2018-12-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income | ¥444.2bn | 2022-01-01 → 2022-12-31 | Cons. | Profit loss IFRS |
| Net income | ¥340.2bn | 2021-01-01 → 2021-12-31 | Cons. | Profit loss IFRS |
| Net income | ¥312.0bn | 2020-01-01 → 2020-12-31d | Cons. | Profit loss IFRS (5-year summary) |
| Net income | ¥361.6bn | 2019-01-01 → 2019-12-31d | Cons. | Profit loss IFRS (5-year summary) |
| Net income | ¥387.4bn | 2018-01-01 → 2018-12-31d | Cons. | Profit loss IFRS (5-year summary) |
| Total assets | ¥6.55T | at 2022-12-31 | Cons. | Assets IFRS |
| Total assets | ¥5.77T | at 2021-12-31 | Cons. | Assets IFRS |
| Total assets | ¥5.38T | at 2020-12-31d | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥5.55T | at 2019-12-31d | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥5.46T | at 2018-12-31d | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥2.93T | at 2022-12-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥2.89T | at 2021-12-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥3.62T | at 2022-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥2.89T | at 2021-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥2.60T | at 2020-12-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥3.54T | at 2022-12-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥2.81T | at 2021-12-31 | Cons. | Equity attributable to owners of parent IFRS |
| Cash & equivalents | ¥866.9bn | at 2022-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥721.7bn | at 2021-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥538.8bn | at 2020-12-31d | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥357.2bn | at 2019-12-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Cash & equivalents | ¥282.1bn | at 2018-12-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Operating cash flow | ¥483.8bn | 2022-01-01 → 2022-12-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥598.9bn | 2021-01-01 → 2021-12-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥519.8bn | 2020-01-01 → 2020-12-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥540.4bn | 2019-01-01 → 2019-12-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥461.4bn | 2018-01-01 → 2018-12-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Investing cash flow | −¥101.8bn | 2022-01-01 → 2022-12-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥97.5bn | 2021-01-01 → 2021-12-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | ¥5.4bn | 2020-01-01 → 2020-12-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥123.6bn | 2019-01-01 → 2019-12-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥383.3bn | 2018-01-01 → 2018-12-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Financing cash flow | −¥306.2bn | 2022-01-01 → 2022-12-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥353.1bn | 2021-01-01 → 2021-12-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥297.4bn | 2020-01-01 → 2020-12-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥333.8bn | 2019-01-01 → 2019-12-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥62.4bn | 2018-01-01 → 2018-12-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| EPS (basic) | ¥249.45 | 2022-01-01 → 2022-12-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥190.76 | 2021-01-01 → 2021-12-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥174.88 | 2020-01-01 → 2020-12-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥195.97 | 2019-01-01 → 2019-12-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥215.31 | 2018-01-01 → 2018-12-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥249.36 | 2022-01-01 → 2022-12-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥190.68 | 2021-01-01 → 2021-12-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥174.8 | 2020-01-01 → 2020-12-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥195.87 | 2019-01-01 → 2019-12-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥215.2 | 2018-01-01 → 2018-12-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| Net assets per share | ¥1,994.78 | at 2022-12-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥1,583.1 | at 2021-12-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥1,421.92 | at 2020-12-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥1,501.12 | at 2019-12-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥1,468.44 | at 2018-12-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Equity ratio | 54.1% | at 2022-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 48.6% | at 2021-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 46.9% | at 2020-12-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 47.9% | at 2019-12-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 48.2% | at 2018-12-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| ROE | 13.9% | 2022-01-01 → 2022-12-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 12.7% | 2021-01-01 → 2021-12-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 12.0% | 2020-01-01 → 2020-12-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 13.2% | 2019-01-01 → 2019-12-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 14.3% | 2018-01-01 → 2018-12-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| Employees | 52,640 | at 2022-12-31 | Cons. | Number of employees |
| Employees | 55,381 | at 2021-12-31 | Cons. | Number of employees |
| Employees | 58,300 | at 2020-12-31d | Cons. | Number of employees |
| Employees | 61,975 | at 2019-12-31d | Cons. | Number of employees |
| Employees | 63,968 | at 2018-12-31d | Cons. | Number of employees |
| Revenue | ¥542.2bn | 2022-01-01 → 2022-12-31 | Standalone | Net sales |
| Revenue | ¥592.2bn | 2021-01-01 → 2021-12-31 | Standalone | Net sales |
| Revenue | ¥596.9bn | 2020-01-01 → 2020-12-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥660.8bn | 2019-01-01 → 2019-12-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥696.3bn | 2018-01-01 → 2018-12-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥64.6bn | 2022-01-01 → 2022-12-31 | Standalone | Operating income |
| Operating income | ¥93.8bn | 2021-01-01 → 2021-12-31 | Standalone | Operating income |
| Ordinary income | ¥273.7bn | 2022-01-01 → 2022-12-31 | Standalone | Ordinary income |
| Ordinary income | ¥278.8bn | 2021-01-01 → 2021-12-31 | Standalone | Ordinary income |
| Ordinary income | ¥240.5bn | 2020-01-01 → 2020-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥279.0bn | 2019-01-01 → 2019-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥190.3bn | 2018-01-01 → 2018-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥310.1bn | 2022-01-01 → 2022-12-31 | Standalone | Income before income taxes |
| Profit before tax | ¥236.2bn | 2021-01-01 → 2021-12-31 | Standalone | Income before income taxes |
| Net income | ¥283.5bn | 2022-01-01 → 2022-12-31 | Standalone | Profit loss |
| Net income | ¥216.9bn | 2021-01-01 → 2021-12-31 | Standalone | Profit loss |
| Net income | ¥241.8bn | 2020-01-01 → 2020-12-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥262.5bn | 2019-01-01 → 2019-12-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥164.6bn | 2018-01-01 → 2018-12-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥2.36T | at 2022-12-31 | Standalone | Assets |
| Total assets | ¥2.49T | at 2021-12-31 | Standalone | Assets |
| Total assets | ¥2.60T | at 2020-12-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥2.61T | at 2019-12-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥2.67T | at 2018-12-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥994.6bn | at 2022-12-31 | Standalone | Liabilities |
| Total liabilities | ¥1.14T | at 2021-12-31 | Standalone | Liabilities |
| Net assets / equity | ¥1.37T | at 2022-12-31 | Standalone | Net assets |
| Net assets / equity | ¥1.34T | at 2021-12-31 | Standalone | Net assets |
| Net assets / equity | ¥1.39T | at 2020-12-31d | Standalone | Net assets |
| Net assets / equity | ¥1.42T | at 2019-12-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥1.49T | at 2018-12-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥193.4bn | at 2022-12-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥238.1bn | at 2021-12-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥159.72 | 2022-01-01 → 2022-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥122.23 | 2021-01-01 → 2021-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥136.27 | 2020-01-01 → 2020-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥147.72 | 2019-01-01 → 2019-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥91.89 | 2018-01-01 → 2018-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥159.66 | 2022-01-01 → 2022-12-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥122.18 | 2021-01-01 → 2021-12-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥136.21 | 2020-01-01 → 2020-12-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥147.65 | 2019-01-01 → 2019-12-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥91.84 | 2018-01-01 → 2018-12-31d | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥188 | 2022-01-01 → 2022-12-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥140 | 2021-01-01 → 2021-12-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥154 | 2020-01-01 → 2020-12-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥154 | 2019-01-01 → 2019-12-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥150 | 2018-01-01 → 2018-12-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥770.57 | at 2022-12-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥757.1 | at 2021-12-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥782.73 | at 2020-12-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥798.18 | at 2019-12-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥832.87 | at 2018-12-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 57.9% | at 2022-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 54.0% | at 2021-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 53.5% | at 2020-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 54.2% | at 2019-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 55.9% | at 2018-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 20.9% | 2022-01-01 → 2022-12-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 15.9% | 2021-01-01 → 2021-12-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 17.2% | 2020-01-01 → 2020-12-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 18.1% | 2019-01-01 → 2019-12-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 10.7% | 2018-01-01 → 2018-12-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 2,000,000,000 | at 2022-12-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 2,000,000,000 | at 2021-12-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 2,000,000,000 | at 2020-12-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 2,000,000,000 | at 2019-12-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 2,000,000,000 | at 2018-12-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 5,819 | at 2022-12-31 | Standalone | Number of employees |
| Employees | 7,154 | at 2021-12-31 | Standalone | Number of employees |
| Employees | 7,366 | at 2020-12-31d | Standalone | Number of employees |
| Employees | 7,464 | at 2019-12-31d | Standalone | Number of employees |
| Employees | 7,457 | at 2018-12-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 86
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | capex | 2022-01-01 → 2022-12-31 | ¥6.6bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-01-01 → 2022-12-31 | ¥9.5bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-01-01 → 2022-12-31 | ¥2.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2022-01-01 → 2022-12-31 | ¥7.5bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-01-01 → 2022-12-31 | −¥40.8bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-01-01 → 2022-12-31 | −¥40.8bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-01-01 → 2022-12-31 | −¥41.1bn |
| Reconciling Itemsreconciling | capex | 2022-01-01 → 2022-12-31 | ¥0 |
| Reconciling Itemsreconciling | revenue | 2022-01-01 → 2022-12-31 | −¥7.9bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-01-01 → 2022-12-31 | −¥7.9bn |
| Reconciling Itemsreconciling | segment profit | 2022-01-01 → 2022-12-31 | −¥52m |
| Reconciling Itemsreconciling | segment profit | 2022-01-01 → 2022-12-31 | −¥52m |
| Reconciling Itemsreconciling | segment profit | 2022-01-01 → 2022-12-31 | −¥52m |
| Pharmaceuticalsreportable segment | capex | 2022-01-01 → 2022-12-31 | ¥2.4bn |
| Pharmaceuticalsreportable segment | employees | at 2022-12-31 | 1331 pure |
| Pharmaceuticalsreportable segment | revenue | 2022-01-01 → 2022-12-31 | ¥82.9bn |
| Pharmaceuticalsreportable segment | revenue external | 2022-01-01 → 2022-12-31 | ¥82.9bn |
| Pharmaceuticalsreportable segment | segment profit | 2022-01-01 → 2022-12-31 | ¥11.1bn |
| Pharmaceuticalsreportable segment | segment profit | 2022-01-01 → 2022-12-31 | ¥11.1bn |
| Pharmaceuticalsreportable segment | segment profit | 2022-01-01 → 2022-12-31 | ¥11.1bn |
| Processed Foodreportable segment | capex | 2022-01-01 → 2022-12-31 | ¥8.2bn |
| Processed Foodreportable segment | employees | at 2022-12-31 | 4297 pure |
| Processed Foodreportable segment | revenue | 2022-01-01 → 2022-12-31 | ¥155.5bn |
| Processed Foodreportable segment | revenue external | 2022-01-01 → 2022-12-31 | ¥155.5bn |
| Processed Foodreportable segment | revenue intersegment | 2022-01-01 → 2022-12-31 | ¥3m |
| Processed Foodreportable segment | segment profit | 2022-01-01 → 2022-12-31 | ¥3.5bn |
| Processed Foodreportable segment | segment profit | 2022-01-01 → 2022-12-31 | ¥3.5bn |
| Processed Foodreportable segment | segment profit | 2022-01-01 → 2022-12-31 | ¥4.2bn |
| Tobaccoreportable segment | capex | 2022-01-01 → 2022-12-31 | ¥83.8bn |
| Tobaccoreportable segment | employees | at 2022-12-31 | 46163 pure |
| Tobaccoreportable segment | revenue | 2022-01-01 → 2022-12-31 | ¥2.42T |
| Tobaccoreportable segment | revenue external | 2022-01-01 → 2022-12-31 | ¥2.42T |
| Tobaccoreportable segment | revenue intersegment | 2022-01-01 → 2022-12-31 | ¥332m |
| Tobaccoreportable segment | segment profit | 2022-01-01 → 2022-12-31 | ¥754.0bn |
| Tobaccoreportable segment | segment profit | 2022-01-01 → 2022-12-31 | ¥754.0bn |
| Tobaccoreportable segment | segment profit | 2022-01-01 → 2022-12-31 | ¥679.4bn |
| —segment total | capex | 2022-01-01 → 2022-12-31 | ¥94.4bn |
| —segment total | revenue | 2022-01-01 → 2022-12-31 | ¥2.66T |
| —segment total | revenue external | 2022-01-01 → 2022-12-31 | ¥2.66T |
| —segment total | revenue intersegment | 2022-01-01 → 2022-12-31 | ¥335m |
| —segment total | segment profit | 2022-01-01 → 2022-12-31 | ¥768.7bn |
| —segment total | segment profit | 2022-01-01 → 2022-12-31 | ¥768.7bn |
| —segment total | segment profit | 2022-01-01 → 2022-12-31 | ¥694.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | capex | 2021-01-01 → 2021-12-31 | ¥3.2bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2021-01-01 → 2021-12-31 | ¥7.2bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2021-01-01 → 2021-12-31 | ¥2.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2021-01-01 → 2021-12-31 | ¥5.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2021-01-01 → 2021-12-31 | −¥43.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2021-01-01 → 2021-12-31 | −¥43.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2021-01-01 → 2021-12-31 | −¥37.5bn |
| Reconciling Itemsreconciling | capex | 2021-01-01 → 2021-12-31 | −¥7m |
| Reconciling Itemsreconciling | revenue | 2021-01-01 → 2021-12-31 | −¥5.5bn |
| Reconciling Itemsreconciling | revenue intersegment | 2021-01-01 → 2021-12-31 | −¥5.5bn |
| Reconciling Itemsreconciling | segment profit | 2021-01-01 → 2021-12-31 | −¥120m |
| Reconciling Itemsreconciling | segment profit | 2021-01-01 → 2021-12-31 | −¥120m |
| Reconciling Itemsreconciling | segment profit | 2021-01-01 → 2021-12-31 | −¥120m |
| Pharmaceuticalsreportable segment | capex | 2021-01-01 → 2021-12-31 | ¥6.0bn |
| Pharmaceuticalsreportable segment | revenue | 2021-01-01 → 2021-12-31 | ¥80.4bn |
| Pharmaceuticalsreportable segment | revenue external | 2021-01-01 → 2021-12-31 | ¥80.4bn |
| Pharmaceuticalsreportable segment | segment profit | 2021-01-01 → 2021-12-31 | ¥11.1bn |
| Pharmaceuticalsreportable segment | segment profit | 2021-01-01 → 2021-12-31 | ¥11.1bn |
| Pharmaceuticalsreportable segment | segment profit | 2021-01-01 → 2021-12-31 | ¥11.3bn |
| Processed Foodreportable segment | capex | 2021-01-01 → 2021-12-31 | ¥10.7bn |
| Processed Foodreportable segment | revenue | 2021-01-01 → 2021-12-31 | ¥147.2bn |
| Processed Foodreportable segment | revenue external | 2021-01-01 → 2021-12-31 | ¥147.2bn |
| Processed Foodreportable segment | revenue intersegment | 2021-01-01 → 2021-12-31 | ¥1m |
| Processed Foodreportable segment | segment profit | 2021-01-01 → 2021-12-31 | ¥4.0bn |
| Processed Foodreportable segment | segment profit | 2021-01-01 → 2021-12-31 | ¥4.0bn |
| Processed Foodreportable segment | segment profit | 2021-01-01 → 2021-12-31 | ¥2.9bn |
| Tobaccoreportable segment | capex | 2021-01-01 → 2021-12-31 | ¥81.0bn |
| Tobaccoreportable segment | revenue | 2021-01-01 → 2021-12-31 | ¥2.10T |
| Tobaccoreportable segment | revenue external | 2021-01-01 → 2021-12-31 | ¥2.10T |
| Tobaccoreportable segment | revenue intersegment | 2021-01-01 → 2021-12-31 | ¥411m |
| Tobaccoreportable segment | segment profit | 2021-01-01 → 2021-12-31 | ¥639.2bn |
| Tobaccoreportable segment | segment profit | 2021-01-01 → 2021-12-31 | ¥639.2bn |
| Tobaccoreportable segment | segment profit | 2021-01-01 → 2021-12-31 | ¥522.4bn |
| —segment total | capex | 2021-01-01 → 2021-12-31 | ¥97.7bn |
| —segment total | revenue | 2021-01-01 → 2021-12-31 | ¥2.32T |
| —segment total | revenue external | 2021-01-01 → 2021-12-31 | ¥2.32T |
| —segment total | revenue intersegment | 2021-01-01 → 2021-12-31 | ¥412m |
| —segment total | segment profit | 2021-01-01 → 2021-12-31 | ¥654.3bn |
| —segment total | segment profit | 2021-01-01 → 2021-12-31 | ¥654.3bn |
| —segment total | segment profit | 2021-01-01 → 2021-12-31 | ¥536.7bn |
| Pharmaceuticalsreportable segment | employees | at 2022-12-31 | 732 pure |
| Processed Foodreportable segment | employees | at 2022-12-31 | 23 pure |
| Tobaccoreportable segment | employees | at 2022-12-31 | 4667 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 2,113
| Item | Context | Value | Unit |
|---|---|---|---|
| Comprehensive income IFRS (5-year summary) | Prior3YearDuration | 365816000000 | JPY |
| Comprehensive income IFRS (5-year summary) | Prior2YearDuration | 132883000000 | JPY |
| Comprehensive income IFRS (5-year summary) | Prior1YearDuration | 540258000000 | JPY |
| Comprehensive income IFRS (5-year summary) | CurrentYearDuration | 998229000000 | JPY |
| Total equity IFRS (5-year summary) | Prior4YearInstant | 2700445000000 | JPY |
| Total equity IFRS (5-year summary) | Prior3YearInstant | 2743611000000 | JPY |
| Total equity IFRS (5-year summary) | Prior2YearInstant | 2599495000000 | JPY |
| Total equity IFRS (5-year summary) | Prior1YearInstant | 2886081000000 | JPY |
| Total equity IFRS (5-year summary) | CurrentYearInstant | 3616761000000 | JPY |
| Total assets IFRS (5-year summary) | Prior4YearInstant | 5461400000000 | JPY |
| Total assets IFRS (5-year summary) | Prior3YearInstant | 5553071000000 | JPY |
| Total assets IFRS (5-year summary) | Prior2YearInstant | 5381382000000 | JPY |
| Total assets IFRS (5-year summary) | Prior1YearInstant | 5774209000000 | JPY |
| Total assets IFRS (5-year summary) | CurrentYearInstant | 6548078000000 | JPY |
| Equity to asset ratio IFRS (5-year summary) | Prior4YearInstant | 1468.44 | |
| Equity to asset ratio IFRS (5-year summary) | Prior3YearInstant | 1501.12 | |
| Equity to asset ratio IFRS (5-year summary) | Prior2YearInstant | 1421.92 | |
| Equity to asset ratio IFRS (5-year summary) | Prior1YearInstant | 1583.10 | |
| Equity to asset ratio IFRS (5-year summary) | CurrentYearInstant | 1994.78 | |
| Basic earnings loss per share IFRS (5-year summary) | Prior4YearDuration | 215.31 | |
| Basic earnings loss per share IFRS (5-year summary) | Prior3YearDuration | 195.97 | |
| Basic earnings loss per share IFRS (5-year summary) | Prior2YearDuration | 174.88 | |
| Basic earnings loss per share IFRS (5-year summary) | Prior1YearDuration | 190.76 | |
| Basic earnings loss per share IFRS (5-year summary) | CurrentYearDuration | 249.45 | |
| Diluted earnings loss per share IFRS (5-year summary) | Prior4YearDuration | 215.20 | |
| Diluted earnings loss per share IFRS (5-year summary) | Prior3YearDuration | 195.87 | |
| Diluted earnings loss per share IFRS (5-year summary) | Prior2YearDuration | 174.80 | |
| Diluted earnings loss per share IFRS (5-year summary) | Prior1YearDuration | 190.68 | |
| Diluted earnings loss per share IFRS (5-year summary) | CurrentYearDuration | 249.36 | |
| Ratio of owners equity to gross assets IFRS (5-year summary) | Prior4YearInstant | 0.4817 | |
| Ratio of owners equity to gross assets IFRS (5-year summary) | Prior3YearInstant | 0.4795 | |
| Ratio of owners equity to gross assets IFRS (5-year summary) | Prior2YearInstant | 0.4688 | |
| Ratio of owners equity to gross assets IFRS (5-year summary) | Prior1YearInstant | 0.4865 | |
| Ratio of owners equity to gross assets IFRS (5-year summary) | CurrentYearInstant | 0.5407 | |
| Rate of return on equity IFRS (5-year summary) | Prior4YearDuration | 0.1430 | |
| Rate of return on equity IFRS (5-year summary) | Prior3YearDuration | 0.1316 | |
| Rate of return on equity IFRS (5-year summary) | Prior2YearDuration | 0.1197 | |
| Rate of return on equity IFRS (5-year summary) | Prior1YearDuration | 0.1270 | |
| Rate of return on equity IFRS (5-year summary) | CurrentYearDuration | 0.1394 | |
| Price earnings ratio IFRS (5-year summary) | Prior4YearDuration | 12.15 | |
| Price earnings ratio IFRS (5-year summary) | Prior3YearDuration | 12.41 | |
| Price earnings ratio IFRS (5-year summary) | Prior2YearDuration | 12.02 | |
| Price earnings ratio IFRS (5-year summary) | Prior1YearDuration | 12.17 | |
| Price earnings ratio IFRS (5-year summary) | CurrentYearDuration | 10.67 | |
| Cash flows from used in operating activities IFRS (5-year summary) | Prior4YearDuration | 461389000000 | JPY |
| Cash flows from used in operating activities IFRS (5-year summary) | Prior3YearDuration | 540410000000 | JPY |
| Cash flows from used in operating activities IFRS (5-year summary) | Prior2YearDuration | 519833000000 | JPY |
| Cash flows from used in operating activities IFRS (5-year summary) | Prior1YearDuration | 598909000000 | JPY |
| Cash flows from used in operating activities IFRS (5-year summary) | CurrentYearDuration | 483799000000 | JPY |
| Cash flows from used in investing activities IFRS (5-year summary) | Prior4YearDuration | -383307000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 21 of 21 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |